Novel prognostic tissue markers in congestive heart failure
被引:6
|
作者:
Stone, James R.
论文数: 0引用数: 0
h-index: 0
机构:
Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
Harvard Univ, Sch Med, Boston, MA 02114 USAMassachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA
Stone, James R.
[1
,2
,3
]
机构:
[1] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
Heart failure is a relatively common disorder associated with high morbidity, mortality, and economic burden. Better tools to predict outcomes for patients with heart failure could allow for better decision making concerning patient treatment and management and better utilization of health care resources. Endomyocardial biopsy offers a mechanism to pathologically diagnose specific diseases in patients with heart failure, but such biopsies can often be negative, with no specific diagnostic information. Novel tissue markers in endomyocardial biopsies have been identified that may be useful in assessing prognosis in heart failure patients. Such tissue markers include ubiquitin, Gremlin-1, cyclophilin A, and heterogeneous nuclear ribonucleoprotein C. In some cases, tissue markers have been found to be independent of and even superior to clinical indices and serum markers in predicting prognosis for heart failure patients. In some cases, these novel tissue markers appear to offer prognostic information even in the setting of an otherwise negative endomyocardial biopsy. (C) 2014 Elsevier Inc. All rights reserved.